HC Wainwright & Co. Maintains Buy on Niagen Bioscience, Lowers Price Target to $11

Benzinga Newsdesk www.benzinga.com Negative 67.6%

Neg 67.6% Neu 0% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Niagen Bioscience (NASDAQ:NAGE) with a Buy and lowers the price target from $12 to $11.